The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | G | Genito urinary system and sex hormones | |
2 | G02 | Other gynecologicals | |
3 | G02A | Oxytocics | |
4 | G02AD | Prostaglandins |
Code | Title | |
---|---|---|
G02AD01 | Dinoprost | |
G02AD02 | Dinoprostone | |
G02AD03 | Gemeprost | |
G02AD04 | Carboprost | |
G02AD05 | Sulprostone | |
G02AD06 | Misoprostol |
Active Ingredient | Description | |
---|---|---|
Carboprost |
Carboprost is a synthetic 15-methyl analogue of dinoprost (prostaglandin F2 alpha). Administered intramuscularly carboprost stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. It is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and for the treatment of postpartum hemorrhage due to uterine atony, which has not responded to conventional methods of management. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle: vomiting, diarrhea, nausea, fever and flushing. Carboprost may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended. |
|
Dinoprost |
|
|
Dinoprostone |
|
|
Gemeprost |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is a prostaglandin E1 analogue. Both in pregnant and non-pregnant animals, it causes contraction of the uterus and causes softening and decreases resistance of cervical tissue. Gemeprost depresses placental and uterine blood flow but those actions are secondary to the main uterine stimulation. |
|
Misoprostol |
Misoprostol is an analogue of naturally occurring prostaglandin E1 which promotes peptic ulcer healing and symptomatic relief. Misoprostol protects the gastroduodenal mucosa by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion. |
|
Sulprostone |
|
Title | Information Source | Document Type | |
---|---|---|---|
ANGUSTA Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CERVAGEM Vaginal pessary | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CERVIDIL Vaginal insert | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
HEMABATE Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PRANDIN E2 Vaginal Gel | Marketing Authorisation Holder | MPI, Generic | |
PREPIDIL Gel | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
PROSTIN E2 Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PROSTIN E2 Vaginal tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TOPOGYNE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |